Myfortic (Mycophenolic Acid)

Mycophenolic acid blocks the enzyme inosine monophosphate dehydrogenase, which is essential for making guanosine nucleotides. This limits the proliferation of activated T‑ and B‑lymphocytes, reducing the immune response that can lead to graft rejection or autoimmune damage.

The dosage of Myfortic is individualized. A qualified prescriber determines the appropriate strength and frequency based on the patient’s transplant type, renal function, and other clinical factors. Patients should follow the prescribing information provided by their healthcare professional.

The safety of Myfortic in pregnancy and lactation has not been fully established. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and this decision must be made by the treating physician.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) is an antimetabolite that specifically inhibits lymphocyte proliferation, whereas calcineurin inhibitors such as cyclosporine act by blocking T‑cell activation pathways. Myfortic is often combined with a calcineurin inhibitor to achieve synergistic immunosuppression while offering a different side‑effect profile.

Myfortic tablets should be stored at room temperature, below 25 °C, in the original blister pack or bottle. Keep them away from moisture, heat and direct sunlight to maintain product stability.

Myfortic is taken orally as an enteric‑coated tablet. It is usually swallowed whole with water, and may be taken with or without food as directed by the prescriber. The exact timing relative to other medications should follow the healthcare provider’s instructions.

Serious risks include severe infections due to immune suppression, leukopenia or other blood‑cell abnormalities, and an increased long‑term risk of certain malignancies. Patients should be monitored regularly for signs of infection, abnormal blood counts and any unexpected symptoms.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet components. It should be used with caution in individuals with severe renal impairment, active infections, or a history of malignancy, and only under close medical supervision.